The primary objective of this study was to comprehensively evaluate alterations in serum levels of NfL and FLCs in CIDP patients undergoing treatment to limit neuronal damage. The gene discussed is NEFL; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.